March 26, 2026
Dear Reader,
On paper, Clostridioides difficile looked like low-hanging fruit: two exotoxins, a well-defined high-risk population, and a simple premise, to neutralize toxins A and B before antibiotics disrupt the microbiome and prevent disease.Yet after more than a decade and multiple large programs, there is still no licensed vaccine, only a series of near misses.
The rationale was sound. Toxoid vaccines work for tetanus and diphtheria, and early studies in C. difficile showed reassuring safety and strong antitoxin responses. However, phase 3 trials in older, comorbid populations proved far less predictable. CLOVER missed its primary endpoint, GSK has stepped back, and what seemed straightforward has turned into a lesson in the complexity of real-world efficacy in nosocomial disease.
In this issue, we look at how Elaris is reviving Valneva’s toxoid candidate and Pfizer’s 32,000-participant BEETHOVEN trial, and why this still matters for high-risk patients in the coming decade.
We also cover the extremely high incidence of TBEV infection vs. disease in Austria, myocarditis after mRNA COVID-19 vaccines, global and regional updates on COVID-19 vaccines, global polio eradication and current outbreaks, and this week’s evidence brief, along with fresh insights to support your vaccine counselling. The infographic shows the principles of mRNA vaccine production.
Enjoy the reading!
With all my best wishes – stay healthy and get the vaccine doses you need!
Warm regards,
Editor-in-Chief, Global Health Press
 |
Your go-to source for concise
updates on the latest developments in the world of vaccines. This week's VacciNEWS viewpoint: |
 |
Infographic of the weekVacciTUTOR is our CME-accredited online course dedicated to vaccines and vaccination. Developed by leading international researchers, the course offers over 60 comprehensive chapters covering fundamental topics such as microbiology and immunology, as well as detailed insights into vaccine-preventable diseases and their corresponding vaccines. Concise bullet-point summaries are available free of charge to support quick reference and learning. Feel free to download today’s mRNA vaccines: from sequence to shot infographic. » |
|
The TBE Newsletter – March EditionThis month in the TBE newsletter, reading “High risk of TBE infection among non-vaccinated individuals in a highly vaccinated population”, the article highlights that even in regions with strong overall vaccination coverage, the risk of tick-borne encephalitis (TBE) remains substantially higher among unvaccinated people compared to those vaccinated, reinforcing the importance of personal vaccination for effective protection.Last month's Snapshot:
|
Be part of the Global Health Press Community - id-ea.org
Join our GHP community and access exclusive, subscriber-only articles, expert reviews, and in-depth features. By becoming a subscriber, you’ll stay ahead of the news with the latest vaccines and vaccination updates. Enjoy content designed specifically for our engaged audience.
We’re also excited to welcome contributors who share our passion for advancing the field of vaccines and vaccination,
public health and education. Whether it’s submitting an article, serving as a Country Editor, contributing research,
or hosting a webinar, there are many ways to get involved.
Become part of the conversation and strengthen global health together with us. Subscribe and join today!
Contact us at info@globalhealthpress.org to learn more.
| Let’s get the word out! : | |
 |
|
| Like what you read? Forward this email to your friends or colleagues. | |
| Share with your friends |
At Global Health Press Pte Ltd, we are committed to safeguarding your privacy.
Your contact details are never shared with third parties. If you no longer wish to receive updates from us, you can unsubscribe here.
Copyright © 2009-2026 Global Health Press Pte Ltd. Reg. No. 200921795N